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Background: Hepatic steatosis (HS), the most frequent liver disorder, was reported to be an independent predictor
of cardiovascular disease. HS, if combined with the metabolic syndrome (MetS), might have a synergistic effect on
low-density lipoprotein (LDL) particle size.
Methods: Carotid intima-media thickness (IMT) and plaque formation, and HS were diagnosed ultrasonographically,
and the MetS was diagnosed using the ATP III criteria in 274 healthy workers (mean age ± SD, 43.5 ± 7.1 yrs). LDL
particle size was measured with density gradient ultracentrifugation, and subfractions were classified as large,
buoyant LDL I (27.2~28.5 nm) and small, dense LDL III (24.2~25.5). All participants were grouped into three
categories: control, subjects with HS alone and those with both HS and the MetS.
Results: The subjects with HS alone were 84 (30.7%), whereas those with HS and the MetS were 46 (16.8%). LDL
peak particle sizes showed significant negative correlations with carotid mean IMTs. LDL peak particle size and LDL
I (%) decreased significantly in the HS, showing the lowest values in the subjects with both HS and the MetS, and
their association was independent, even adjusted for potential confounders. LDL III also showed independent
associations across the groups.
Conclusion: HS alone was more prevalent than HS combined with the MetS in general population. For the
patients with HS alone, LDL particle size and carotid atherosclerosis were found to fall in the middle of the control
and those with both HS and the MetS.
Introduction
Atherosclerosis and its relevant vascular events includ-
ing cardiovascular disease (CVD), stroke, and peripheral
arterial disease (PAD) have become a leading cause of
disability and mortality in modern society [1]. Increasing
trends of the vascular diseases are universal both in
developed and developing countries [2]. A lifestyle sum-
marized as a lack of physical activity and moderate-to-
high intake of calories seems to be one of the most
important causes of rapidly increasing prevalence of the
metabolic syndrome (MetS) [3], type 2 diabetes mellitus
(DM) [4], dyslipidemia [5], and eventually atherothrom-
botic diseases [2].
The sedentary lifestyle made people more dyslipi-
demic; atherogenic dyslipidemia, consisting of high tri-
glyceride (TG), low high-density lipoprotein (HDL)
cholesterol, and small low-density lipoprotein (LDL)
particle size [6]. Smaller LDL particle size than normal
has been known to be closely associated with the MetS
[7], insulin resistance [8], CVD [9], and PAD [10]. LDL
particle size was reported to be influenced by lipid-low-
e r i n ga g e n t s[ 1 1 ]a sw e l la sb yp h y s i c a le x e r c i s e[ 1 2 ] .
The well-known determinants of LDL particle size
include TG and HDL cholesterol, both of which are the
major components of the MetS [13].
In the present study, it is hypothesized that hepatic
steatosis (HS) could be associated with variable degrees
of atherogenic dyslipidemia, and both LDL particle size
and carotid atherosclerosis might be exacerbated if HS
was combined with the MetS. HS, the most frequent liver
disorder, was reported to be an independent predictor of
CVD [14]. According to the results obtained with a ultra-
sonographical diagnosis for HS and a definition of the
MetS, all subjects in the study were grouped into control,
subjects with HS alone, and those with both HS and the
MetS, and examined for the hypothesis using a cohort
sample of randomly selected hospital workers.
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Study population
The present cross-sectional study was intentionally
designed and executed to investigate relations between
HS and the MetS. The detailed explanation about the
design was reported previously [15]. In brief, according
to the age- and sex-stratified random sampling, 334 hos-
pital workers were randomly selected and among them,
135 men and 158 women (response rate of 87.7%) parti-
cipated in the survey. All participants gave their written
informed consents to the participation in this study, and
the study was approved by the institutional research
ethics committee.
Data collection and measurements
The administered questionnaire was designed to deter-
mine the prior history of CVD, type 2 DM, hyperten-
sion, and medication usage. Information regarding
alcohol-drinking status, as estimated by the frequency,
duration, amount and kind of liquor consumed, was
obtained, and the mean ethanol intake per day was cal-
culated. Smoking status was classified into three cate-
gories: current smokers, ex-smokers, and non-smokers.
Waist circumference was measured, with the subject
standing and wearing no underwear, at the level midway
between the lower rib margin and the iliac crest. Body
mass index (BMI) was calculated by a computer as
weight divided by height squared (kg/m
2).
Abdominal ultrasonography and definition of hepatic
steatosis (HS)
All abdominal ultrasonographic scans were performed
by one radiologist (Y. K. K) who was blinded to the
patients’ histories and laboratory results. His annual
total number of cases of abdominal sonography has
exceeded 5,000 during the past 8 years. Fatty liver mea-
s u r e m e n t sw e r em a d eu s i n ga3 . 5 - M H zc o n v e xp r o b e
(Sequoia, Siemens Medical Solutions, Mountain View,
CA) in all subjects. Hepatic steatosis was diagnosed by
characteristic echo-patterns, according to the conven-
tional criteria (i.e., evidence of a diffuse increase in
echogenicity of the liver as compared with that of the
kidney) [16]. The examiner also assessed the evidence of
chronic hepatitis or liver cirrhosis, including hepatic
nodularity, coarseness of liver parenchyma, and spleno-
megaly. Repeated measurements on the same subjects
gave coefficients of variation (CV) of < 1% for the pre-
sence of fatty liver, as reported early [15].
Definition of the metabolic syndrome (MetS)
The MetS was identified by the presence of three or
more of the following five components, according to
the modified criteria of the Third Adults Treatment
Panel (modified ATP-III) of the National Cholesterol
Education Program (NCEP), with waist cutoffs appropri-
ate for Asian population [13]: 1) abdominal obesity
(waist circumference ≥ 90 cm for men and ≥ 80 cm for
women); 2) high blood pressure (≥ 130/85 mmHg or
use of antihypertensives); 3) high TG (≥ 1.7 mmol/L or
150 mg/dL); 4) low HDL cholesterol (< 1.03 mmol/L
or 40 mg/dL for men and < 1.3 mmol/L or 50 mg/dL
for women); and 5) high fasting glucose (≥ 5.6 mmol/L
or 100 mg/dL).
Carotid intima-media thickness (IMT) and plaque
formation
The measurement of the carotid IMT was conducted
using a higher-frequency 7.0-MHz linear transducer
(Sequoia; Siemens Medical Solutions, Mountain View,
CA) with compound and harmonic imaging to reduce
near-field artifacts [17]. The carotid IMT, a double-line
pattern visualized by echotomography on the far wall of
both distal common carotid arteries (CCA) and proxi-
mal internal carotid arteries (ICA), was measured in a
region free of plaque, and their mean values were calcu-
lated. Atherosclerotic plaque was defined as a focal
structure encroaching the arterial lumen of at least
0.5 mm or 50% of the surrounding IMT value, or
demonstrated a thickness > 1.5 mm as measured from
the media-adventitia interface to the intima-lumen inter-
face [18]. Repeated measurements on the same objects
(30 subjects) gave a CV < 6.2%.
Biochemical investigations
Blood samples were collected in the morning before
breakfast after an overnight fast. Serum biochemistries
were assessed with a Hitachi 7600-110 analyzer (Hitachi
High-Technologies Corporation, Tokyo, Japan). Most
laboratory investigations were described previously in
detail [15]. In addition, serum insulin was determined
by the electrochemiluminescence immunoassay using
Modular Analytics E170 (Roche Diagnostics GmbH,
Mannheim, Germany), and insulin resistance was calcu-
lated by homeostasis model assessment for insulin resis-
t a n c e( H O M A - I R )s c o r e[ 1 9 ] .S e r u mT Ga n dg l u c o s e
were determined enzymatic a l l y( R o c h eD i a g n o s t i c s
GmbH, Mannheim, Germany). HDL cholesterol was
measured enzymatically as cholesterol after selective dis-
ruption of HDL only (Daiichi Pure Chemicals Co., Ltd.,
Japan). Apolipoprotein A-I (apo A-I) and B (apo B)
assays were analyzed by a Roche/Hitachi Modular P
Chemistry analyzer that used an immunoturbidimetric
assay (Roche Diagnostics GmbH, Mannheim, Germany).
Plasma concentration of total homocysteine was mea-
sured by fluorescence polarization immunoassay
(AxSYM, Abbott Laboratories, Abbott Park, IL).
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The peak particle size of LDL was measured by both a
density gradient ultracentrifugation and a pore gradient
lipoprotein system (CBS Scientific, Del Mar, CA) with
commercially available non-denaturing 2-16% polyacry-
lamide gradient gels (Alamo Gels Inc., San Antonio,
TX). Standard markers of polystyrene latex beads
(36 nm), thyroglobulin (17 nm), apoferritin (12.2 nm)
and catalase (10.4 nm) were used to estimate the relative
migration rates of each band. The gels were scanned
with a GS-800 Calibrated Imaging Densitometer (Bio-
Rad Laboratories, Graz, Austria). LDL particle size was
calculated with reference to the relative migration value
of the standard markers [20]. For a quantitative subfrac-
tion analysis, LDL I (if LDL peak particle size was
27.2~28.5 nm) and LDL III (24.2~25.5 nm) were classi-
fied, and their proportions were used in the present
study.
Statistical Analysis
The descriptive data for the major characteristics of the
aforementioned three categories were expressed as the
mean ± standard deviation (SD) or percentage as appro-
priately. An analysis of variance (ANOVA) was used to
determine the statistical differences in the continuous
variables and the chi-square test for trend for categori-
cal variables. For the LDL particle sizes, mean values
and 95% confidence intervals (CI) according to the
three categories and scatter plots with carotid IMTs
were depicted. A general linear model was used to eval-
uate how adjusted mean values of LDL particle sizes
and carotid atherosclerosis varied in the three cate-
gories. Bonferroni tests were applied to correct for mul-
tiple comparisons. Interaction terms like three
categories x variables (i.e., sex) were created, and their
significances were assessed. All statistical analyses were
conducted using SPSS software version 16.0 (SPSS, Chi-
cago, TX)
Results
Among the 293 participants, 15 (5.1%) subjects who had
t h eM e t Sw i t hn oc o m b i n e dH Sa n d4( 1 . 4 % )w h od i d
not undergo abdominal ultrasonographic examinations
were excluded from the present study. Finally, 125 men
and 149 women (93.5%) were analyzed. Excluded sub-
jects showed statistically significantly higher age than
included ones (47.4 ± 7.6 vs. 43.5 ± 7.1 y, p = 0.022),
but percentages of women did not show much differ-
ence (54.4% vs. 47.4%, P = 0.553).
According to the definitions for HS and the MetS, 84
subjects (30.7%) were categorized as the subjects with
HS alone, 46 (16.8%) as those with both HS and the
MetS, and the rest (144 subjects) as control, as shown
in Table 1. Age was not significantly different in the
three groups. A proportion of women was lowest in the
subjects with both HS and the MetS, and the propor-
tions of smokers and alcohol drinkers (more than 20 g/d)
were significantly higher in the subjects with HS.
Total cholesterol, LDL cholesterol, and apo B were
significantly elevated in the subjects with HS alone, even
adjusted for age, sex, alcohol drinking and smoking, as
shown in Table 2. HOMA-IR showed significantly ele-
vated values across the groups with the highest value in
the subjects with both HS and the MetS, and fasting
insulin levels showed a similar trend as HOMA-IR and
reached a borderline significance.
As for LDL peak particle size and the proportions of
large, buoyant LDL particles (LDL I, 27.2~28.5 nm), the
control group had the largest values, whereas the HS and
MetS combined group had the lowest values, as shown in
Figures 1A and 1B. Regarding the proportions of small,
dense LDL particles (LDL III, 24.2~25.5 nm), the control
group had the least values, whereas the combined group
had the largest values as shown in Figure 1C. Scatter plots
of the LDL peak particle size and carotid IMTs of both
mean CCA and ICA showed significant negative correla-
tions, as depicted in Figures 2A and 1B. The correlation
Table 1 Baseline characteristics of the subjects according to hepatic steatosis (HS) and the metabolic syndrome (MetS)
Control HS alone HS with MetS
Characteristics (n = 144) (n = 84) (n = 46) P
a
Age, y 42.9 ± 7.1 43.7 ± 6.7 45.1 ± 7.9 0.178
Women, % 68.1 47.6 23.9 < 0.001
Smoking, ex- and current, % 26.1 39.3 56.5 < 0.001
Alcohol consumption (≥20 g/d), % 15.3 23.8 45.7 < 0.001
ALT, IU/L 18.4 ± 8.8 24.5 ± 14.1** 37.5 ± 24.5***
† < 0.001
Ferritin, ng/ml 51.7 ± 47.5 74.7 ± 62.3* 131.6 ± 106.3***
† < 0.001
Body mass index, kg/m
2 21.8 ± 2.2 24.3 ± 2.3*** 26.0 ± 2.1***
† < 0.001
Values are mean ± SD unless noted otherwise. Components of the metabolic syndrome are not expressed. ALT; alanine aminotransferase.
a P values by analysis of variance (ANOVA) or chi-square test for trend.
*P < 0.05, ** P < 0.01, *** P < 0.001; compared with the control (Bonferroni comparison).
† P < 0.001; compared with the HS alone (Bonferroni comparison).
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ICA, respectively. As for the effect modifiers for the asso-
ciation presented in Figures 1 and 2, neither sex nor other
factors like alcohol consumption and nonalcoholic fatty
liver disease (NAFLD) showed significant interaction
terms (all P for interaction > 0.1).
Both mean CCA and ICA IMTs showed significantly
increased values across the three groups, with the high-
est IMTs in the combined group adjusting for age, sex,
alcohol drinking and smoking, as shown in Table 3. The
percentage of carotid plaque showed similar patterns
with carotid IMTs, with the highest percentage in the
combined group.
The associations between the LDL peak particle size
and the three groups were independent, even adjusted
for the potential confounders including BMI, HOMA-
I R ,a n da p oB ,a ss h o w ni nT a b l e4 .T h es u b j e c t sw i t h
HS alone showed independently lower values of LDL
peak particle size and large, buoyant LDL I (%) than the
control. As for small, dense LDL III (%), a difference
between the subjects with HS alone and the control lost
significance after an adjustment. The subjects with both
HS and MetS showed the lowest values for LDL peak
particle size and LDL I (%), and the highest values for
LDL III (%) among the three categories.
Discussion
The present study showed independent associations of
both hepatic steatosis (HS) and the metabolic syndrome
(MetS) with LDL particle size, even adjusted for the
potential confounders including apo B and HOMA-IR.
And the significant linear trends of LDL particle sizes
supported the original hypothesis that atherogenic dysli-
pidemia could be exacerbated if MetS combined with
HS. The present study further showed that HS itself,
even when HS was not combined with the MetS,
showed significant and independent differences as for
LDL particle sizes compared with the control. Until
now, LDL particle size in HS has been reported only in
patients with type 2 DM [21], but not yet in general
population.
LDL particle size, in nature, is closely related with
serum levels of TG, HDL cholesterol, and insulin resis-
tance [7]. As large amounts of plasma TG are carried or
t r a n s p o r t e db yv e r yl o wd e n s i t yl i p o p r o t e i n( V L D L )
from liver, TG-rich HDL cholesterol which is made by
an action of cholesterol ester transfer protein (CETP)
[22] undergoes hydrolysis by lipoprotein lipase (LPL)
and eventually is degraded by kidney. Then, TG-rich
lipoproteins (TRLs) depletes TG by lipolysis, thus giving
rise to small, dense LDL particles [23]. As for cardiovas-
cular risk, both quality (i.e., the question of how small
LDL peak particle size is) and quantity (i.e., the percen-
tage of small LDL III) of LDL particle size were reported
to be important equally and additively [24], as shown in
Table 3.
The smaller LDL particle size in the subjects with HS
alone than the control could be explained with a con-
cept of hepatic insulin resistance, which occurred pri-
marily [25] and more evidently [26] than peripheral
insulin resistance. Hepatic fat accumulation in HepG2
cells was found to induce serine phosphorylation of
insulin receptor substrate (IRS)-1 and endoplasmic reti-
culum (ER) stress, as previously reported by the authors
[27]. The ER stress, in turn, led to the suppression of
insulin receptor signaling, causing hepatic insulin resis-
tance and an enhanced TG synthesis [28]. The HS alone
in the present study could be regarded as hepatic insulin
resistance with no evident peripheral insulin resistance.
Contrary to LDL particle sizes, both fasting insulin and
Table 2 Adjusted mean values (± SE) of variables on lipid and insulin resistance







Total cholesterol, mmol/L 4.54 ± 0.06 4.92 ± 0.08** 4.88 ± 0.12 0.012 0.002
LDL cholesterol, mmol/L 2.74 ± 0.06 3.09 ± 0.07** 3.00 ± 0.10* 0.001 0.019
Triglyceride, mmol/L 1.11 ± 0.05 1.48 ± 0.07***
†† 2.20 ± 1.00***
†† < 0.001 < 0.001
HDL cholesterol, mmol/L 1.34 ± 0.02 1.23 ± 0.03** 1.09 ± 0.04***
† < 0.001 < 0.001
Lipoprotein(a), mmol/L 0.71 ± 0.05 0.77 ± 0.09 0.67 ± 0.09 0.632 0.699
Apo B, g/L 0.77 ± 0.02 0.88 ± 0.02** 0.91 ± 0.03** < 0.001 < 0.001
Apo A-I, g/L 1.27 ± 0.03 1.23 ± 0.03 1.24 ± 0.05 0.623 0.537
Plsama total homocysteine (tHcy) and HOMA-IR
Plasma tHcy, μmol/L 6.9 ± 0.2 7.2 ± 0.3 7.2 ± 0.4 0.593 0.471
Fasting insulin, μU/ml 5.3 ± 0.5 6.8 ± 0.6 7.2 ± 0.9 0.083 0.056
HOMA-IR 1.3 ± 0.1 1.7 ± 0.2 1.9 ± 0.2* 0.030 0.014
Adjusted for age, sex, alcohol drinking (≥20 g/d), and smoking. LDL, low-density lipoprotein; HDL, high-density lipoprotein; apo B, apolipoprotein B; apo A-I,
apolipoprotein A-I; HOMA-IR; homeostasis model assessment for insulin resistance.
*P < 0.05, ** P < 0.01, *** P < 0.001; compared with the control (Bonferroni adjustment for multiple comparisons).
†P <0 . 0 5 ,
†† P < 0.001; compared with the HS alone (Bonferroni adjustment for multiple comparisons).
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syndrome (MetS). A. Mean values (with 95% CIs) of LDL peak particle size (nm), B. Large, buoyant LDL subfraction I (%), and C. Small, dense
LDL subfraction III (%): All three values showed significant linear associations with the three categories (P < 0.001). * P < 0.01, **P < 0.001;
compared with the control (Bonferroni comparison).
† P < 0.05,
†† P < 0.01; compared with the HS alone.
Figure 2 Scatter plots of carotid intima-media thickness (IMT) and LDL peak particle size. A. A scatter plot of both CCA mean IMT and
LDL peak particle size, r = -0.14, P = 0.021; B. A scatter plot of both ICA mean IMT and LDL peak particle size, r = -0.16, P = 0.010.
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not show any significant differences between the control
and the subjects with HS alone, as shown in Table 2.
NAFLD, which can be defined by alcohol consump-
tion less than 20 g/d (excluding hepatitis B virus and
hepatitis C virus infections) [29], has been reported to
be closely related with subsequent metabolic diseases
[30]. In the present population study, however, the asso-
ciation between HS and LDL particle size was not modi-
fied by alcohol consumption or NAFLD. A recent study
about fatty liver index reported significant associations
among high values of the index, atherosclerosis, and
insulin resistance, where fatty liver was not divided into
alcoholic or nonalcoholic subtypes either [31].
The present study has several limitations. First, HS was
not examined histologically, but diagnosed ultrasonogra-
phically. Although the combination of HS and the MetS
might result in advanced pathologic findings of liver like
steatohepatitis, the authors were unable to define such
changes exactly. However, the abdominal ultrasono-
graphic examination was sufficient to detect the presence
of fatty liver for research purposes [16]. The diagnosis of
fatty liver using ultrasonography was reported to have a
somewhat low sensitivity and high specificity [32], thus
the present control group was believed to be selected
appropriately. Second, the present study did not collect
the information on food or nutrient consumption such as
niacin [33]. So the present study could not delineate
whether the LDL particle size was modified by the addi-
tional nutrient supplement. Third, the present result did
not adjust further with TG or HDL-cholesterol, although
they were known as the most important determinants of
LDL particle sizes. But, the three categorizations in the
study used the MetS which included TG and HDL cho-
lesterol as important components for a definition [13].
Hence, the additional adjustment of the two components
seemed to be an overcorrection in the present model.
Last, the present results were obtained from a cross-sec-
tional design. Accordingly a subsequent longitudinal
study may be warranted to establish a biologic plausibil-
ity. Currently, a new study is underway to perform a chy-
lomicron-clearance test for the same subjects involved in
the present study.
In summary, the present study demonstrated that LDL
peak particle size was negatively correlated with carotid
IMT and plaque, and that hepatic fatty infiltration (HS)
was independently associated with the LDL particle size
in terms of both quantity and quality, irrespective of the
co-existence of the MetS. HS, even when there is a
subtle change to be recognized, should be regarded and
monitored carefully as an early hepatic manifestation of
atherogenic dyslipidemia.
Table 3 Adjusted mean values (± SE) of carotid intima-media thickness (IMT) and plaque
Control HS alone HS with MetS P value (Between groups) P value (Linear trend)
Carotid mean IMT
Both CCA mean IMT, mm 0.67 ± 0.01 0.68 ± 0.01 0.72 ± 0.02* 0.042 0.013
Both ICA mean IMT, mm 0.68 ± 0.01 0.69 ± 0.01 0.74 ± 0.02* 0.032 0.015
Carotid plaque
Carotid plaque, crude, % 11.1 ± 0.3 14.3 ± 0.4 32.6 ± 0.5**
† 0.002 0.001
Carotid plaque, adjusted, % 12.5 ± 0.3 13.8 ± 0.4 29.8 ± 0.5*
† 0.017 0.007
Adjusted for age, sex, alcohol drinking (≥20 g/d), and smoking. CCA; common carotid artery, ICA; internal carotid artery.
*P < 0.05, ** P < 0.01; compared with the control (Bonferroni adjustment for multiple comparisons).
† P < 0.05; compared with the HS alone (Bonferroni adjustment for multiple comparisons).
Table 4 Adjusted mean values (± SE) of LDL particle sizes
Control HS alone HS with MetS P value (Between groups) P value (Linear trend)
LDL peak particle size, nm
Model 1 27.6 ± 0.1 27.2 ± 0.1* 26.8 ± 0.2** 0.001 < 0.001
Model 2 27.6 ± 0.1 27.3 ± 0.1 26.9 ± 0.2** 0.009 0.003
LDL I (27.2~28.5 nm), %
Model 1 30.8 ± 0.6 27.9 ± 0.7* 25.9 ± 1.1** 0.001 0.001
Model 2 30.5 ± 0.6 28.0 ± 0.7* 26.7 ± 1.0* 0.005 0.004
LDL III, (24.2~25.5 nm), %
Model 1 19.3 ± 0.4 20.8 ± 0.5 22.2 ± 0.8** 0.006 0.002
Model 2 19.5 ± 0.4 20.8 ± 0.5 21.7 ± 0.7* 0.026 0.013
Model 1 included age, sex, alcohol drinking (≥20g/d), smoking, BMI, and HOMA-IR.
Model 2 included variables in the model 1 plus total cholesterol, LDL cholesterol, and apo B.
* P < 0.05, ** P < 0.01; compared with the control (Bonferroni adjustment for multiple comparisons).
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